Nuvalent Shares Soar Following GSK's Acquisition Announcement

Deep News

06/09

Shares of the American pharmaceutical company Nuvalent, Inc. surged nearly 39% after British biopharmaceutical firm GlaxoSmithKline PLC announced its acquisition of the company for $10.6 billion.

This all-cash transaction values Nuvalent at approximately $124 per share. Nuvalent currently has two drugs for a specific type of lung cancer under review by the U.S. Food and Drug Administration.

In a press release, GlaxoSmithKline PLC CEO Luke Mears stated that this acquisition will provide the company with immediate new sales growth opportunities. Shares of the pharmaceutical giant traded in the U.S. fell 1% in pre-market trading on Tuesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1171432341"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171432341\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171432341?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171432341","market":"us","top_or_hot":-1,"title":"Nuvalent Shares Soar Following GSK's Acquisition Announcement","media":"Deep News","content":"<p>Shares of the American pharmaceutical company <b>Nuvalent, Inc.</b> surged nearly 39% after British biopharmaceutical firm <b>GlaxoSmithKline PLC</b> announced its acquisition of the company for $10.6 billion.<br><br>This all-cash transaction values Nuvalent at approximately $124 per share. Nuvalent currently has two drugs for a specific type of lung cancer under review by the U.S. Food and Drug Administration.<br><br>In a press release, <b>GlaxoSmithKline PLC</b> CEO Luke Mears stated that this acquisition will provide the company with immediate new sales growth opportunities. Shares of the pharmaceutical giant traded in the U.S. fell 1% in pre-market trading on Tuesday.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvalent Shares Soar Following GSK's Acquisition Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvalent Shares Soar Following GSK's Acquisition Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-06-09 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of the American pharmaceutical company <b>Nuvalent, Inc.</b> surged nearly 39% after British biopharmaceutical firm <b>GlaxoSmithKline PLC</b> announced its acquisition of the company for $10.6 billion.<br><br>This all-cash transaction values Nuvalent at approximately $124 per share. Nuvalent currently has two drugs for a specific type of lung cancer under review by the U.S. Food and Drug Administration.<br><br>In a press release, <b>GlaxoSmithKline PLC</b> CEO Luke Mears stated that this acquisition will provide the company with immediate new sales growth opportunities. Shares of the pharmaceutical giant traded in the U.S. fell 1% in pre-market trading on Tuesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"","article_id":"1171432341","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171432341","pubTimestamp":1781007636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of the American pharmaceutical company Nuvalent, Inc. surged nearly 39% after British biopharmaceutical firm GlaxoSmithKline PLC announced its acquisition of the company for $10.6 billion.This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","GSKH":"GSK plc ADRhedged","BK4007":"制药","NUVL":"Nuvalent, Inc.","GSK.UK":"葛兰素史克"},"translate_title":"葛兰素史克宣布收购后，Nuvalent股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":1,"GSK":1,"GSKH":1,"NUVL":1},"content_text":"Shares of the American pharmaceutical company Nuvalent, Inc. surged nearly 39% after British biopharmaceutical firm GlaxoSmithKline PLC announced its acquisition of the company for $10.6 billion.This all-cash transaction values Nuvalent at approximately $124 per share. Nuvalent currently has two drugs for a specific type of lung cancer under review by the U.S. Food and Drug Administration.In a press release, GlaxoSmithKline PLC CEO Luke Mears stated that this acquisition will provide the company with immediate new sales growth opportunities. Shares of the pharmaceutical giant traded in the U.S. fell 1% in pre-market trading on Tuesday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}